Side effect profile and adherence to in the treatment of Multiple Sclerosis with interferon beta-la

David C. Mohr*, William Likosky, Arne C. Boudewyn, Peter Marietta, Pat Divyer, Judy Van Der Wende, Donald E. Goodkin

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

70 Scopus citations

Abstract

This study examines the course of patient-reported side effects during the first 4 months of treatment for multiple sclerosis (MS) with interferon beto-la (IFNP-la), and the relationship of those side effects to discontinuation of medication. Flu-like symptoms, muscle aches and chills decreased over the first 2 months of treatment but did not change over the second 2 months. Loss of feeling or numbness, tingling and depression increased over 4 months, however these side effects were generally mild. Loss of feeling or numbness and tingling at 2 month follow-up were significantly related to discontinuation of IFNβ-la by 4 month follow-up.

Original languageEnglish (US)
Pages (from-to)487-489
Number of pages3
JournalMultiple Sclerosis
Volume4
Issue number6
DOIs
StatePublished - Jan 1 1998

Keywords

  • Compliance
  • Interferon
  • Multiple sclerosis
  • Side effects

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Side effect profile and adherence to in the treatment of Multiple Sclerosis with interferon beta-la'. Together they form a unique fingerprint.

Cite this